These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3103520)

  • 21. Kinetics of the somatomedin C/insulin-like growth factor I: response to exogenous growth hormone (GH) in GH-deficient children.
    Blethen SL; Daughaday WH; Weldon VV
    J Clin Endocrinol Metab; 1982 May; 54(5):986-90. PubMed ID: 7037825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternatives to growth hormone.
    Lancet; 1989 Apr; 1(8642):820-2. PubMed ID: 2564906
    [No Abstract]   [Full Text] [Related]  

  • 23. [Efficacy of GH-releasing hormone and biosynthetic GH in a group of children with growth hormone deficiency].
    Biscaldi I; Fiori A; Moretta A; Valtorta A
    Medicina (Firenze); 1990; 10(2):145-6. PubMed ID: 2273946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current developments in the treatment of growth delay using growth hormone].
    Wit JM
    Tijdschr Kindergeneeskd; 1986 Dec; 54(6):170-6. PubMed ID: 3103256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of pigs as an animal model to evaluate the efficacy, potency and specificity of two growth hormone releasing factor analogues.
    Dubreuil P; Brazeau P; Moreau S; Farmer C; Coy D; Abribat T
    Growth Horm IGF Res; 2001 Jun; 11(3):173-86. PubMed ID: 11735232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor.
    Borges JL; Blizzard RM; Evans WS; Furlanetto R; Rogol AD; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1984 Jul; 59(1):1-6. PubMed ID: 6427267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained improvement in growth velocity and recovery from suboptimal growth hormone (GH) secretion after treatment with human pituitary GH-releasing hormone-(1-44)-NH2.
    Lifshitz F; Lanes R; Pugliese M; Fort P; Perez I; Puentes S; Cervantes C; Gunczler P; Chasalow FI; Recker B
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1255-60. PubMed ID: 1430086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominant dwarfism in transgenic rats by targeting human growth hormone (GH) expression to hypothalamic GH-releasing factor neurons.
    Flavell DM; Wells T; Wells SE; Carmignac DF; Thomas GB; Robinson IC
    EMBO J; 1996 Aug; 15(15):3871-9. PubMed ID: 8670892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
    Giavoli C; Cappiello V; Corbetta S; Ronchi CL; Morpurgo PS; Ferrante E; Beck-Peccoz P; Spada A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):81-7. PubMed ID: 15212648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible hypothyroidism in growth hormone-deficient children treated with human growth hormone.
    Lippe BM; Van Herle AJ; LaFranchi SH; Uller RP; Lavin N; Kaplan SA
    J Clin Endocrinol Metab; 1975 Apr; 40(4):612-8. PubMed ID: 165211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
    Saggese G; Federico G; Cinquanta L
    Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth increments with low dose intermittent growth hormone and fluoxymesterone in first year of therapy in hypopituitarism.
    Kirkland RT; Clayton GW
    Pediatrics; 1979 Mar; 63(3):386-8. PubMed ID: 220585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facilitation of the growth promoting effect of growth hormone (GH) by an antibody to methionyl-GH.
    Suh BK; Jorgensen EV; Root AW
    J Pediatr Endocrinol Metab; 1995; 8(2):97-102. PubMed ID: 7584712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia in a patient treated with growth hormone.
    Aktan M; Tanakol R; Nalçaci M; Dinçol G
    Endocr J; 2000 Aug; 47(4):471-3. PubMed ID: 11075729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs recently released in Belgium. Recombinant methionyl human growth hormone, synthetic growth hormone-releasing factor, somatostatin.
    Harvengt C
    Acta Clin Belg; 1987; 42(1):62-5. PubMed ID: 2884791
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibodies to human growth hormone. Development during therapy with human growth hormone.
    Frasier SD; Smith FG
    Am J Dis Child; 1966 Nov; 112(5):383-8. PubMed ID: 4162038
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic agents produced by genetic engineering: Quo vadis? The example of growth hormone and its releasing factor. Satellite symposium. Toulouse-Labège, May 29-30, 1985.
    Horm Res; 1986; 24(2-3):201-28. PubMed ID: 3093353
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment with human growth hormones in 1986].
    Job JC
    Ann Endocrinol (Paris); 1986; 47(5):372-7. PubMed ID: 3103520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of human growth hormone administration on growth rate and growth-stimulating activity of serum, measured by lymphocyte bioassay in hypopituitary children.
    Bozzola M; Lorini R; Schimpff RM; Severi F; Job JC
    Horm Metab Res; 1986 Apr; 18(4):264-7. PubMed ID: 3710421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men.
    Rosenthal SM; Hulse JA; Kaplan SL; Grumbach MM
    J Clin Invest; 1986 Jan; 77(1):176-80. PubMed ID: 3080472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.